Mineralys Therapeutics reported a net loss of $36.9 million for Q3 2025, a notable improvement from $56.3 million in the prior year. This was primarily driven by a decrease in research and development expenses due to the conclusion of the lorundrostat pivotal program. The company also significantly strengthened its balance sheet with cash, cash equivalents, and investments reaching $593.6 million, up from $198.2 million at the end of 2024, following a public equity financing.

Mineralys Therapeutics reported a net loss of $43.3 million for the second quarter of 2025, an increase from $41.0 million in the same period last year. The company's cash, cash equivalents, and investments significantly increased to $324.9 million, providing funding into 2027. Research and development expenses slightly decreased, while general and administrative expenses rose.

Mineralys Therapeutics reported a net loss of $42.2 million for the first quarter of 2025, an increase from $31.5 million in the same period last year, primarily due to increased research and development and general and administrative expenses. The company ended the quarter with a strong cash position of $343.0 million following a public equity financing.

Mineralys Therapeutics reported a net loss of $24.4 million for the fourth quarter of 2023, compared to a net loss of $9.1 million for the same period in 2022. Cash, cash equivalents and investments were $239.0 million as of December 31, 2023. The company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations, into 2026.

Mineralys Therapeutics reported its Q4 and full year 2022 financial results, highlighting the upcoming pivotal clinical program for lorundrostat and the completion of its IPO in February 2023. The company is focused on developing treatments for diseases driven by elevated aldosterone.